DP
PTHS

Diadema Partners’s Pelthos Therapeutics PTHS Stock Holding History

Diadema Partners’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700K Hold
24,773
– – 0.09% 112
2026
Q1 		$520K Sell
24,773
-227
-0.9% -$5.38K 0.09% 108
2025
Q4 		$775K Buy
25,000
+14,502
+138% +$418K 0.13% 101
2025
Q3 		$294K Buy
+10,498
New +$255K 0.08% 108

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Diadema Partners's PTHS Position: Q2 2026 in Review

Diadema Partners held its Pelthos Therapeutics (PTHS) position steady in Q2 2026 at 24,773 shares worth $700K. The position accounts for 0.09% of the portfolio, ranked #112.

Diadema Partners first reported a position in PTHS in Q3 2025 and has held it in 4 quarters since. The position peaked at $775K in Q4 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Diadema Partners held 24,773 shares of Pelthos Therapeutics worth $700K as of Q2 2026.
  • Diadema Partners left its Pelthos Therapeutics share count unchanged in Q2 2026.
  • Pelthos Therapeutics made up 0.09% of Diadema Partners's portfolio in Q2 2026, its #112 holding.
  • Diadema Partners first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Diadema Partners's Pelthos Therapeutics position peaked at $775K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.